An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Pfizer

Status and phase

Completed

Phase 2

Conditions

Dermatomyositis

Treatments

Drug: Anti-Beta Interferon (PF-06823859)

Study type

Interventional

Funder types

Industry

Identifiers

NCT05192200

2021-004787-10 (EudraCT Number)

C0251008

Details and patient eligibility

About

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

Enrollment

24 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants aged ≥18 and ≤80 with moderate to severe dermatomyositis (DM), that have completed the treatment period of a qualifying study.
Capable of giving signed informed consent.
Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Exclusion criteria

Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
Participants who met discontinuation criteria at any point during the participating qualifying studies.
Participants with an ongoing safety event in the qualifying studies which, in the opinion of the investigator or sponsor, is an ongoing safety concern OR the participant has met safety monitoring criteria in the qualifying study that has not resolved.